The Evidence Base Post 05 November 2026

Your guide to ISPOR Europe 2026

The Evidence Base

ISPOR Europe 2026 will bring the global HEOR community together in Vienna from November 8–11. As an official media partner, The Evidence Base will be reporting from the meeting and working with organizations across the sector to bring readers research highlights, expert perspectives and conversations from the conference.

The Austria Center Vienna will host researchers, healthcare decision-makers, industry, patients and policy experts for four days of health economics and outcomes research (HEOR) at ISPOR Europe, November 8–11, 2026. This year’s theme, “Shaping the Future of Access Through Science and Policy,” connects a program spanning evidence generation, health technology assessment (HTA), real-world evidence (RWE), AI, value assessment, pricing and market access.

Key details

Dates: November 8–11, 2026
Location: Austria Center Vienna, Bruno-Kreisky-Platz 1, 1220 Wien, Austria
Registration: Still open; register here
Social media: #ISPOREurope

Exploring Vienna: what to know before you go

If you have time between sessions, Vienna is easy to explore by public transport, with the U-Bahn, trams and buses connecting the Austria Center Vienna with the city center. The venue is served by the U1 line at Kaisermühlen VIC, making areas such as Stephansplatz and Karlsplatz straightforward to reach.

November can be chilly, so layers and a coat are advisable. And for those looking for an early taste of Christmas, Vienna’s Weihnachtsmärkte begin opening in early November, offering the chance to visit one of the city’s traditional Christmas markets while you are in town.

The Evidence Base coverage

As an official media partner for ISPOR Europe, The Evidence Base team will be in Vienna covering the discussions, research and emerging themes from across the meeting.

Over the past week, our preview series has already taken a closer look at some of the questions we expect to feature prominently: what the first year of Joint Clinical Assessment has taught us; what it will take for RWE to become decision-grade; where human oversight should remain as AI becomes more autonomous; whether the definition of value in healthcare is changing; and how Europe can protect access and innovation as global pricing policies collide.

Our partner content

Alongside that broader editorial coverage, we will also be working with a number of partners throughout the meeting. From poster research and expert interviews to discussions around the issues shaping evidence generation and access, here is where you can find them in Vienna and what we will be covering together.

Adigens Health

Where to find them: Booth 824

At ISPOR Europe 2026, Adigens Health will focus on some of the key methodological questions shaping evidence generation, from causal inference and AI to the design of observational studies for HTA.

On Monday, November 9 (1:45 – 2:45pm), Radek Wasiak will be joined by Miguel Hernán, Gorana Capkun (Merck KGaA) and Michael Haft (Xplain Data) for “The Future of Causal Inference: How Large (or Small) Role Will AI Play?”, exploring where AI could strengthen causal inference and where methodological judgment still matters.

Miguel will also moderate the workshop on Wednesday, November 11 (8:00 – 9:00am), “Biases that Generate Immortal Time: A Structural Diagnosis and Practical Solutions for HTA Submissions”, which will include Adigens Health colleague Xabier García de Albéniz.

We recently caught up with Xabier to discuss the design choices that often determine whether an observational study withstands scrutiny, why many failures originate at the protocol stage and how sponsors can generate RWE that is fit for decision-making.

Look out for: Our new Adigens Health Spotlight, including the interview with Huseyin Naci (LSE Health), as well as our upcoming webinar exploring what the first Joint Clinical Assessments reveal about comparative effectiveness and future evidence generation.

Cardinal Health

Where to find them: Booth 1214

Cardinal Health will be at ISPOR Europe 2026 as a year-round ISPOR Mission Partner and exhibitor, with a focus on how pragmatic trials and connected real-world data can generate evidence that is more relevant to decision-making.

On Tuesday, November 10 (3:15 – 3:45pm), Bruce Feinberg and Nicholas Lazarou will present “From Routine Care to Decision-Grade Evidence: Scaling Pragmatic Trials Across Health Systems”. Drawing on a pragmatic study across 20 community gastroenterology practices, the session will examine how randomization can be embedded into routine care and scaled across health systems, including through federated study models.

Look out for: How can routine care become a setting for randomized, decision-ready evidence generation? Cardinal Health’s ISPOR Europe 2026 session approaches that question through pragmatic trials. Our recent Deep Dives with Cardinal Health, “Following the patient journey: How connected data and evolving methods are reshaping real-world evidence” and “Connecting real-world datasets to provide deeper insights into the patient journey”, provide background on how connected, multisource data can give a more complete view of the patient journey and strengthen RWE generation.

Cencora

Where to find them: Booth 715

A Mission Partner and exhibitor, Cencora will bring a broad program spanning EU HTA, market access, AI and the changing global pricing environment.

On Monday (3:15 – 4:15pm), Ruairi O'Donnell will moderate “One Assessment, Many Decisions: The Future of Country-Level HTA After JCA,” exploring what happens after the European assessment and how national HTA and reimbursement decisions may evolve. On Tuesday (11:45 – 12:15), Erika Wissinger will join “The Next Generation of HEOR: Career Pathways in an AI-Augmented Field,” while on Wednesday (10:00 – 11:00) Casper Paardekooper will moderate “The Triple Challenge: How Do Global Pricing Dynamics, with US MFN Policy, China’s Rise, and European Policies Converge and Impact European Competitiveness?”

Cencora will also present research across economic evaluation, reimbursement and market access, including studies on orphan drugs, HTA requirements across the DACH region, biosimilar uptake and the impact of changing US pricing policies.

Look out for: Patient access, innovation and equity were central to our recent coverage of a Cancer Patients Europe webinar on Most-Favored-Nation pricing across European health systems. Casper Paardekooper discussed the potential global implications of US pricing reform, including early signs of delayed launches and product withdrawals in some European markets. For readers following those developments, his ISPOR Europe session examines how US MFN policy interacts with China’s growing influence and European competitiveness.

Flatiron Health

Where to find them: Booth 1018

Flatiron Health will bring a substantial research presence to ISPOR Europe 2026, with seven accepted research contributions spanning AI-enabled data curation, real-world oncology data and evidence generation across healthcare systems.

On Tuesday (3:15–3:45pm), Arun Sujenthiran and Qianyi Zhang will present “Setting the global standard: What it takes to scale AI-curated oncology data across countries,” examining what is needed to apply AI-enabled approaches consistently across different clinical and data environments.

Look out for: Ahead of ISPOR Europe, we caught up with Arun Sujenthiran about Flatiron’s work extending the VALID framework to UK prostate cancer data. The interview examines what can be standardized across countries, where validation needs to remain context-specific and what this means for confidence in AI-generated RWD. Their session at the conference will build on this research, focusing on scaling AI-curated oncology data internationally.

Lumanity

Where to find them: Booth 611

As an ISPOR Alliance Partner, Lumanity will have one of the larger teams in Vienna, with 38 experts listed across HEOR, market access, patient-centered outcomes and RWE, together with colleagues from PHARMO.

JCA will be a major focus for Lumanity’s experts on Monday, November 9. Suzette Matthijsse will moderate “Navigating Europe’s New Era of Health Policy Reform” (10:30 – 11:30am) and “First Wave, First Lessons: Multi-Stakeholder Insights from the Initial Joint Clinical Assessments,” (1:45 – 2:45pm). She will also moderate the Exhibit Hall Theater session “Preparing Orphan Medicinal Products for JCA: Strengthening the Evidence Package” (3:15 – 3:45pm), featuring Miranda Cooper and Triona Zelesnik.

The wider research program spans RWE, evidence synthesis, economic evaluation and HTA, with posters covering topics from AI-assisted literature reviews and PHARMO data linkages to expert elicitation in NICE appraisals, severity modifiers and quantitative bias analysis. Two studies have also been named Top 5% finalists for the ISPOR Europe 2026 Research Presentation Award.

Look out for: What happens when trial evidence does not directly match the population or setting of interest? Our recent Evidence Transportability Spotlight with Lumanity examined the methodological challenges of applying evidence across populations, healthcare systems and decision contexts. It offers background for readers following Lumanity’s discussions in Vienna on JCA, comparative effectiveness, RWE and evidence synthesis.

Precision AQ

Where to find them: Booth 918

Precision AQ will bring more than 30 posters, podium presentations and workshops to ISPOR Europe 2026, covering HTA, JCA, market access, evidence synthesis, pricing policy and payer insights shaping healthcare decision-making across global markets.

JCA is a particularly strong theme, with six studies examining different parts of the emerging European assessment landscape, from evidence prioritization and prognostic-factor identification to payer readiness and early methodological lessons from the first assessments. Several studies have also been selected for discussion in research podium sessions, extending the program beyond the poster hall.

A further methodological highlight is Tuesday’s workshop “Modern Synthesis Methods for Estimating Subgroup-Specific Treatment Effects” (1:45 – 2:45pm), featuring Harlan Campbell, which will examine approaches for estimating treatment effects when evidence is needed for specific subgroups.

Look out for: Precision AQ’s research provides a useful cross-section of several of the issues running through this year’s meeting, particularly how changing HTA and pricing requirements are influencing evidence generation and global access strategy.

RTI Health Solutions

Where to find them: Booth 914

A year-round ISPOR sponsor, RTI Health Solutions will have a broad presence in Vienna, with presentations spanning patient-centered outcomes, RWE, health economics, evidence synthesis, AI and JCA. Their program includes a Sunday short course on designing patient-centered strategies for drug development and value, alongside posters and presentations across the three main conference days.

RTI will also contribute to the methodological discussions around observational evidence. Julia Vila Guilera will join Miguel Hernán and Xabier García de Albéniz (Adigens Health) for the workshop on Wednesday (8:00 – 9:00am) examining how biases arise and how they can be addressed in studies intended to support HTA.

RTI’s JCA research covers both vaccines and orphan medicines. On Tuesday, Louise Hartley and Lacey Lopez will present research examining whether the current JCA framework is fit for vaccines ahead of their inclusion in 2030. Vijay D’Souza and colleagues will discuss methodological lessons from the first JCA of tovorafenib and what they mean for future orphan dossiers.

Look out for: Earlier planning for the evidence challenges facing orphan medicines was the focus of our recent feature with RTI Health Solutions, “From PICOs to comparative evidence: Preparing orphan medicines for EU Joint Clinical Assessment.” In Vienna, readers can explore both lessons from the first assessments and the question of how the JCA framework may need to accommodate other evidence challenges, including vaccines.

Thermo Fisher Scientific

Where to find them: Booth 511

Thermo Fisher Scientific/PPD will have a broad presence at ISPOR Europe 2026, with sessions spanning JCA, rare disease evidence and the changing role of expertise in AI-enabled HEOR.

On Monday (12:15 – 1:15pm), the symposium “One JCA, many decisions: Building an evidence strategy for portability across Europe” will examine how evidence strategies can be designed to travel across European markets while still meeting national decision-making needs. Speakers include Caoimhe Rice, Martin Parkinson, Carla Dias Barbosa and Victoria Federico Paly (Takeda Oncology).

Jaime Caro will also contribute to two wider debates: “Train the economist or hire the engineer? The future of expertise in AI-native HEOR” (Tuesday, 1:45 – 2:45pm) and “How should evidence be assessed in rare diseases?” (Wednesday, 8:00 – 9:00am), bringing methodological and workforce perspectives into the program.

Look out for: Uncertainty around long-term outcomes, effectiveness and implementation is the focus of our recent feature with Thermo Fisher Scientific, “Overcoming barriers to cell and gene therapy adoption with real-world evidence.” Part of our wider work together on evidence generation, the feature examines how RWE can help address those uncertainties. The Vienna program considers evidence for decisions across different technologies, populations and European markets.

Truveta

Where to find them: Booth 1222

As an ISPOR Alliance Partner, Truveta will bring a broad RWE program to Vienna, with research spanning GLP-1 use, cardiovascular risk, food insecurity, blood pressure control and other questions that illustrate how large-scale, continuously updated real-world data can support faster evidence generation.

On Monday (3:15 – 3:45pm), Ryan Ahern will also present “Real-Time Intelligence: AI-Enabled Insights to Drive Evidence Strategy,” exploring how AI can help researchers use daily refreshed RWD to identify emerging trends, refine research questions and prioritize future studies.

Look out for: For background on Truveta’s work, our feature “Delivering real-time, data-driven insights across the evidence lifecycle” examines how more timely RWD can support evidence planning and decision-making. Our webinar “Uncovering unmet need: Using real-time RWD to close gaps in care and access” focuses on using rapidly updated data to identify gaps in care. Ryan Ahern’s Vienna session considers the next question: how AI-enabled insights from those data could help shape evidence strategy.

Follow The Evidence Base from Vienna

Our team will be following the conversations developing across the program, speaking with experts and highlighting research that deserves a closer look. Expect interviews, research highlights, Peek Behind the Poster features and updates from Vienna, alongside our coverage of the wider themes shaping HEOR, HTA, RWE and market access.

Follow use on LinkedIn for live updates throughout the meeting. And for exclusive post-event analysis and session round-ups, register on our site to receive regular updates.

And if you are attending ISPOR Europe 2026, we hope this guide helps you find some of the people, research and conversations worth seeking out – and we look forward to seeing many of you in Vienna.